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Key points
 NMDA receptors are neurotransmitter-gated ion channels that are critically involved in brain
cell communication
 Variations in genes encoding NMDA receptor subunits have been found in a range of neuro-
developmental disorders.
 We investigated a de novo genetic variant found in patients with epileptic encephalopathy that
changes a residue located in the ion channel pore of the GluN2A NMDA receptor subunit.
 We found that this variant (GluN2AN615K) impairs physiologically important receptor
properties: it markedly reduces Mg2+ blockade and channel conductance, even for receptors
in which one GluN2AN615K is co-assembled with one wild-type GluN2A subunit.
 Our findings are consistent with the GluN2AN615K mutation being the primary cause of the
severe neurodevelopmental disorder in carriers.
Abstract NMDA receptors are ionotropic calcium-permeable glutamate receptors with a
voltage-dependence mediated by blockade by Mg2+. Their activation is important in signal
transduction, as well as synapse formation and maintenance. Two unrelated individuals
with epileptic encephalopathy carry a de novo variant in the gene encoding the GluN2A
NMDA receptor subunit: a N615K missense variant in the M2 pore helix (GRIN2AC1845A).
We hypothesized that this variant underlies the neurodevelopmental disorders in carriers
and explored its functional consequences by electrophysiological analysis in heterologous
systems. We focused on GluN2AN615K co-expressed with wild-type GluN2 subunits in physio-
logically relevant triheteromeric NMDA receptors containing two GluN1 and two distinct
GluN2 subunits, whereas previous studies have investigated the impact of the variant in
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diheteromeric NMDA receptors with two GluN1 and two identical GluN2 subunits. We found
that GluN2AN615K-containing triheteromers showed markedly reduced Mg2+ blockade, with
a value intermediate between GluN2AN615K diheteromers and wild-type NMDA receptors.
Single-channel conductance was reduced by four-fold in GluN2AN615K diheteromers, again with
an intermediate value in GluN2AN615K-containing triheteromers. Glutamate deactivation rates
were unaffected. Furthermore, we expressed GluN2AN615K in cultured primary mouse cortical
neurons, observing a decrease in Mg2+ blockade and reduction in current density, confirming
that the variant continues to have significant functional impact in neuronal systems. Our results
demonstrate that the GluN2AN615K variant has substantial effects on NMDA receptor properties
fundamental to the roles of the receptor in synaptic plasticity, even when expressed alongside
wild-type subunits. This work strengthens the evidence indicating that the GluN2AN615K variant
underlies the disabling neurodevelopmental phenotype in carriers.
(Received 14 October 2018; accepted after revision 2 January 2019; first published online 2 January 2019)
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Introduction
The NMDA receptor is an ionotropic voltage-dependent
glutamate receptor with important roles in synaptic signal
transduction and plasticity. NMDA receptor dysfunction
has been identified in diverse neuropsychiatric disorders
(Paoletti et al. 2013). Unlike AMPA- and kainate-type
glutamate receptors, it shows high Ca2+ permeability
(MacDermott et al. 1986) and voltage-dependent Mg2+
blockade, which allows it to act as amolecular coincidence
detector (Mayer et al. 1984; Nowak et al. 1984). NMDA
receptors are heterotetramers comprised of two GluN1
and two GluN2 subunits of which four different subunits
have been cloned (GluN2A-D) (Watanabe et al. 1992;
Monyer et al. 1994). The identity of the GluN2 subunits
in the receptor impacts on receptor properties important
in synaptic plasticity (Wyllie et al. 2013). Diheteromeric
GluN1/GluN2B receptors probably form the commonest
forebrain receptor composition prenatally but, after
GluN2A expression increases postnatally (Bar-Shira et al.
2015), triheteromeric GluN1/GluN2A/GluN2B receptors
comprise a major proportion of NMDA receptors,
particularly in the hippocampus (Gray et al. 2011; Rauner
& Ko¨hr, 2011; Tovar et al. 2013).
The rapid expansion of whole-exome sequencing over
the last decade has shown that many regions of the
gene encoding GluN2A (GRIN2A) are intolerant of
variation in healthy controls (Ogden et al. 2017) and,
instead, a large number of rare and de novo variants
(>100) have been identified in patients with a range of
neurodevelopmental disorders, most commonly epilepsy
aphasia syndromes or other epileptic disorders, but also
intellectual disability, autism, attention deficit hyper-
activity disorder and schizophrenia (XiangWei et al.
2018). At the most severe end of the phenotypic
spectrum are epileptic encephalopathies, where epileptic
activity is considered to contribute to severe cognitive
and behavioural impairment (Scheffer et al. 2017).
Around half of disease-associated GRIN2A variants are
gene-disrupting and around half are missense variants,
potentially resulting in NMDA receptors with altered
function, requiring electrophysiological interrogation for
confirmation. This has been a clinically useful strategy,
with personalized treatment being offered based on
a functional analysis of the variant (Pierson et al.
2014). However, it is improbable that all variants are
disease-causing: some are inherited from phenotypically
normal parents and some are in regions of the protein that
probably exhibit variation without deleterious functional
impact (less highly conserved, or more variation pre-
sent in healthy controls). Furthermore, of those variants
where functional consequences have been assessed, a
range of effects have been found, some predominantly
‘gain-of-function’, some predominantly ‘loss-of-function’
(Swanger et al. 2016) and some with no effect (Marwick
et al. 2017). For these reasons, it is important to identify
the functional consequences, if any, of a given variant
before giving a genetic diagnosis or embarking on targeted
treatment.
The large and increasing number of GRIN2A variants
(and variants in other genes) found inpatientswith neuro-
developmental disorders means that some prioritization
for functional investigation needs to be applied. The
variant that we selected for intensive further study
was GluN2AN615K. This variant was selected because it
affects a residue that is already known to be crucial
in interacting with Mg2+ ions, the ‘N+1’ asparagine
(Wollmuth et al. 1998). Missense mutations affecting this
residue have a high probability of influencing receptor
function. Second, the variant has good genetic evidence
of disease-association: it has arisen de novo in two
unrelated individuals with similar phenotypes (Endele
et al. 2010; Allen et al. 2016). Both individuals presented
with early-onset epileptic encephalopathy, associated with
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severe or profound intellectual disability and electro-
encephalogram abnormalities. Furthermore, so far, the
residue has not been found to bemutated in 60 706 people
without severe paediatric disease (Exome Aggregation
Consortium database, accessed 3 September 2018).
The GluN2AN615K variant was the first missense
GRIN2A variant identified as potentially disease causing
and some functional work on its consequences has
already been performed when expressed as diheteromers:
GluN2AN615K has been found to reduce Mg2+ blockade
and Ca2+ permeability and impact channel blocker
potency but not to affect glutamate or glycine potency
(Endele et al. 2010; Pierson et al. 2014). However, no pre-
vious work has investigated the impact of this variant
when expressed in triheteromers with one wild-type
and one mutated GluN2 subunit. This insight would
be clinically relevant, both because the variant is pre-
sent heterozygously and because the majority of NMDA
receptors in key regions of the adolescent and adult brain
are probably GluN1/GluN2A/GluN2B triheteromers.
Moreover, no previous work has investigated the impact
of the variant on NMDA receptors expressed in neurons,
where neuron-specific trafficking and regulation could
potentially negate or compensate for the impact of the
variant.
In the present study, we employed a recently developed
technique to express triheteromeric NMDA receptors
containing only one variant subunit in HEK293T cells
and assessed the impact of the variant on physiologically
relevant receptor properties important for synaptic trans-
missionusing electrophysiological recordings. In addition,
we expressed the mutant subunit in primary cultured
neurons and found that the GluN2AN615K mutation had a
marked impact on key physiological properties of NMDA
receptors even in thepresenceofwild-type subunits,which
is consistent with a role in the pathogenesis of the epileptic
encephalopathies experienced by its carriers.
Methods
Ethical approval
Experiments conducted during the course of this study
received approval from the University of Edinburgh’s
Animal Welfare Ethical Review Board. Animal breeding
and maintenance and experimental procedures were
performed in accordance with the UK Animals (Scientific
Procedures) Act 1986 under the authority of Project
Licence 60/4290 (D.J.A.W.). Animal experiments adhered
to the ethical principles required by The Journal of Physio-
logy (Grundy, 2015). Mice were housed under a standard
12:12 h light/dark cycle and received food and water ad
libitum. E17.5 CD1mice (sex not determined) supplied by
Charles River (Margate, UK), were culled by decapitation
(a Schedule 1 Method) shortly following culling of the
dam by cervical dislocation (a Schedule 1 method). Dams
were typically 12–22 weeks old.
Mutagenesis
The cDNA for wild-type human NMDA subunit
GluN1-1a (hereafter GluN1) and GluN2A (GenBank
accession codes: NP 015566, NP 000824) (Hedegaard
et al. 2012) were gifts from Dr Hongjie Yuan (University
of Emory, Atlanta, GA, USA). The GluN2 cDNAs for
triheteromer experiments have been described previously:
wild-type rat GluN2A (D13211) and GluN2B (U11419),
GluN2AC1, GluN2AC2, GluN2BAC1 and GluN2BAC2
(Hansen et al. 2014). Expression of GluN1 in HEK293T
cells was achieved as described previously (Yi et al. 2018)
using a plasmid DNA construct with enhanced green
fluorescent protein (eGFP) inserted between the cyto-
megalovirus promoter in pCI-neo and the open reading
frame of rat GluN1 (U08261) (i.e. eGFP and GluN1 were
not expressed as a fusion protein). This DNA construct
produces high expression of eGFP for identification
of transfected cells and maintains a linear relationship
between eGFP and GluN1 expression. All cDNAs were
in pCI-neo. Site-directed mutagenesis was performed
via PCR with overlapping mutagenizing oligonucleotides
using a thermostable Pfu high fidelity DNA polymerase
(New England Biolabs, Ipswich, MA, USA). The PCR
product was recircularized into a viable plasmid using an
InFusion HD kit (Clontech, Mountain View, CA, USA).
The double-stranded mutant DNA was transformed
into TOP10 Competent Cells (Life Tech, Grand Island,
NY, USA). Clones were amplified then DNA extracted
using QIAPrep Spin MiniPrep Kit (Qiagen, Venlo, The
Netherlands) in accordance with the manufacturer’s
instructions. The mutations were verified by Sanger
sequencing through the mutated region.
Preparation and transfection of HEK293T cells
Forwhole-cell experiments, human embryonic kidney 293
cells containing the SV40 largeT–antigen (HEK293T) cells
were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% dialysed fetal bovine serum,
10 U mL–1 penicillin and 10 mg mL–1 streptomycin).
HEK293T cells were chosen for their propensity
to grow singly rather than in clumps, facilitating
electrophysiological experiments involving rapid solution
application. Cells were passaged twice weekly and plated
onto cover slips precoated in poly-D-lysine (0.1 mg mL–1)
to give a density of 10–30% on the day of recording.
HEK293T cells were transfected using the calcium
phosphate precipitation method. Plasmids containing
rGluN1-1a eGFP and the rGluN2 subunits of interest
were mixed in a 1:1 mass ratio and diluted to 200 g L–1
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with water. To transfect four wells of a 24-well plate,
10 μL of cDNA was mixed with 25 μL of 1 M CaCl2
and 100 μL of 2 × Bes (50 mM Bes, 280 mM NaCl and
1.5 mM Na2HPO4, pH 6.95), then mixed by pipetting.
After 10–15 min, 50 μL of this mixture was added
dropwise to each well. After 4–6 h, the media was
replaced with fresh media supplemented with NMDA
receptor antagonists [D-2-amino-5-phosphonopentanoic
acid (200 μM) and 7-chlorokynurenic acid (200 μM)].
Recordings were made 24 h post transfection.
HEK293T for single-channel experiments were prepared
similarly with minor differences: Dulbecco’s modified
Eagle’s medium was supplemented with Glutamax-I
(Thermo Fisher, Waltham, MA, USA) and 1% anti-
biotic/antimycotic and the NMDA receptor antagonists
used to avoid excitotoxicity post transfection were
100 μM D-2-amino-5-phosphonopentanoic acid and
10 μM 5,7-dichlorokynurenic acid.
Whole-cell, voltage clamp recordings in HEK293T cells
Transfected HEK293T cells were identified by eGFP
expression (excitation at 470 nm, coolLED pE-100;
coolLED Ltd, Andover, UK). Whole-cell, patch clamp
recordings were performed using an Axopatch 200B
amplifier (Molecular Devices, Sunnydale, CA, USA) at
room temperature. The signal was then filtered using an
8 kHz 8-pole low-pass filter (–3 dB Bessel; Frequency
Devices, Ottawa, IL, USA) and digitized at 20 kHz using
a Digidata 1440A analogue-digital interface (Molecular
Devices) using Clampex software (Molecular Devices).
Patch pipettes were made from thin-walled borosilicate
glass (TW150F-4; World Precision Instruments, Sarasota,
FL, USA) using a P-1000 puller (Sutter Instruments,
Novato, CA, USA) to give a resistance of 4–5 M when
filled with an internal solution containing (in mM): 141
K-gluconate, 2.5 NaCl, 10 Hepes and 11 EGTA (pH
7.3 with KOH) (300 mosmol L−1). The extracellular
solution was composed of (in mM): 150 NaCl, 10 Hepes,
3 KCl, 0.5 CaCl2, 0.01 EDTA and 20 D-mannitol (pH 7.4
with NaOH). Rapid solution exchange (open tip solution
exchange with 10–90% rise times of 0.7–0.9 ms) was
achieved using a two-barrel theta-glass pipette controlled
by apiezoelectric translator (SiskiyouCorporation,Grants
Pass, OR, USA). Cells with glutamate-evoked responses of
less than 100 pA or greater than 1000 pA were rejected, to
reduce error fromnoise and to avoid leakof undesired sub-
unit pairings (Hansen et al. 2014). To calculate glutamate
deactivation rates, multicomponent exponential decay
curves were fitted to macroscopic response time courses
in ChanneLab software (Synaptosoft, Fort Lee, NJ, USA).
tweighted was calculated as : (% amplitudefast ∗ tfast)
+ (% amplitudeslow ∗ tslow)
Single-channel, voltage clamp recordings
in HEK293T cells
Single-channel, voltage clamp recordings were made at
room temperature from cell-attached patches formed on
HEK293T cells placed in a solution that contained (in
mM): 150NaCl, 2.8 KCl, 10Hepes, 2 CaCl2, 10 glucose and
0.1 glycine (pH 7.35 with NaOH) (300–330 mosmol L−1).
Patches were recorded at a range of holding potentials.
Transfected cells were identified by eGFP expression
as above. Patch pipettes were made from thick-walled
borosilicate glass (GC150F-7.5; Harvard Apparatus,
Cambridge, MA, USA) using a P-87 puller (Sutter
Instruments, Novato, CA, USA) and fire-polished to give
a resistance of 6–12 M when filled with the external
solution plus agonist (glutamate 1 mM). Currents were
recorded using an Axopatch 200B amplifier (Molecular
Devices). Data were filtered at 2 kHz and digitized at
20 kHz via a BNC-2090A analogue-digital interface
(National Instruments, Newbury, UK) using WinEDR
software (Strathclyde Electrophysiology Software,
Strathclyde, UK).
WinEDR v3 (Strathclyde Electrophysiology Software)
was used to idealize the traces (using a transition
threshold of 50% of the predominant conductance level
and a 100 μs open and shut resolution) and to fit
Gaussian curves to amplitude histograms. The relative
proportion of time spent in a given conductance state was
calculated byfitting areas under the amplitude histograms.
To improve accuracy of amplitude estimates, a 1 ms
minimum open time duration was applied. Because the
membrane potential was not known, the patch potential
was unknown. Therefore, recordings were made at a
range of pipette potentials (+40 to +180 mV) and
the current plotted against voltage: the slope (fitted by
linear regression) gave the conductance. Mean open times
were calculated using openings at one pipette potential,
with a 1 ms minimum open time duration applied, and
fitted using single exponentials in WinEDR. Transitions
between subconductance statesweremanually coded from
inspection of all openings with duration>1 ms at a single
pipette potential. Traces were excluded if: R2 < 0.9 for the
linear regression, fewer than three pipette potentials were
recorded from, or fewer than 20 openings occurred at a
given pipette potential.
Preparation and transfection of neurons
Neuronal culturing and transfection was performed as
described previously (Marwick et al. 2017). Shortly
following decapitation, brains were microdissected in
medium containing (in mM): 8.8 Na2SO4, 27 K2SO4,
5.3 MgCl2, 0.23 CaCl2, 0.9 Hepes, 0.001% phenol red,
18 D-glucose and 0.0005 kynurenic acid (adjusted to pH
7.35 using NaOH). Cortices were incubated for 40 min
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at 37°C in papain enzyme (36,000 USP units mL–1)
(Worthington Biochemical Corporation, Lakewood, NJ,
USA) then washed and triturated in NeuroBasal A
medium (Thermo Fisher) (supplemented with 1% rat
serum; Harlan Laboratories, Indianapolis, IN, USA),
1 × B-27 supplement, 1% antibacterial/antimycotic and
1mM glutamine). Opti-MEM (supplemented with 20 mM
glucose and 1% antibacterial/antimycotic) was added to
the cell suspension to give an end concentration of 1 hemi-
sphere per 7 mL, and 0.5 mL was plated onto a glass
coverslip (diameter 13 mm) precoated with poly-D-lysine
(1.33% w/v in H2O) and laminin (0.5% w/v) (Roche,
Basel, Switzerland) in 24-well plates. Plates were kept
for 2.5 h in a humidified 5% CO2 incubator at 37°C
before the cell suspension was removed and replaced with
supplemented NeuroBasal A. On days in vitro (DIV) 4,
1 mL well–1 of supplemented NeuroBasal A additionally
containing9.6mMcytosineβ-D-arabinofuranosidehydro-
chloride (a DNA replication inhibitor that prevents glial
overproliferation) was added to the cells.
Neurons were transfected on DIV 7 or 8 with
plasmids containing cDNA for wild-type and mutant
GluN2A subunits, or the inert control β globin, using
Lipofectamine 2000 (Thermo Fisher) (hereafter referred
to as lipofectamine) in serum free non-trophic trans-
fection medium composed of: 10% minimum essential
media (+Earles, –L-glutamine), 88% salt-glucose-glycine
(comprising in mM 114 NaCl, 26 NaHCO3, 5.3 KCl, 1
MgCl2, 2 CaCl2, 10 Hepes, 1 glycine, 30 D-glucose and 0.5
sodium pyruvate, with phenol red 0.001%) (Bading et al.
1993) supplemented with 1% antibiotic/antimycotic and
1% insulin–transferrin–selenium supplement. For each
coverslip, 575 ng of plasmid DNA comprising a 2:1 mass
ratio ofGluN2A/GluN2B and eGFP cDNAwasmixedwith
2.3 μL of lipofectamine. The cotransfection rate was 96%
(data not shown). Electrophysiological recordings were
performed48 h post transfection.
Whole-cell, voltage clamp recordings
in cultured neurons
Electrophysiological recordings in cultured neurons were
performed as described previously (Marwick et al. 2017).
Recordings were made at room temperature with neurons
superfused (flow rate of 2 mL min–1) with external
recording solution composed of (in mM) 150 NaCl, 2.8
KCl, 10 Hepes, 2 CaCl2, 10 glucose, 0.1 glycine and 0.003
TTX (pH 7.35 using NaOH) (300–330 mosmol L−1).
Transfected cells were identified using eGFP expression
(excitation at 470 nm, coolLED pE-100; coolLED Ltd).
Then, 150 μM NMDA was applied briefly twice to
trigger desensitizationuntil a steady responsewas achieved
(10 s) at which point 1 mM MgCl2 was co-applied until
the response plateaued. Cells were then perfused with
3 μM ifenprodil for 1 min before the experiments were
repeated. Solution application was manually controlled.
Patch pipettes were made from thick-walled borosilicate
glass (GC150F-7.5; Harvard Apparatus) using a P-87
puller (Sutter Instruments) to give a resistance of 2–4M
when filled with internal solution containing (in mM):
141 K-gluconate, 2.5 NaCl, 10 Hepes and 11 EGTA (pH
7.3 with KOH) (300–330 mosmol L−1). Currents were
recorded using an Axopatch 200B amplifier (Molecular
Devices). Data were filtered at 2 kHz and digitized
at 20 kHz via a National Instruments BNC-2090A
analogue–digital interface (National Instruments) using
WinEDR software. Neurons were voltage clamped at
–65 mV, and recordings were rejected if the holding
current was greater than 150 pA or if the series resistance
was greater than 30 M, or increased by greater than
20% during the course of the recording. Capacitance
was calculated by calculating the area under the current
response to a 5 mV test pulse plotted against time
(giving the charge) and dividing by the voltage of
the test pulse. Current density was then calculated as
current/capacitance.
Statistical analysis
Data are presented as the mean ± SEM. Graphs depict
individual cells (circles),means (columns) and SEM(error
bars). N refers to number of cells. R, version 3.1.2 (R
Core Team, 2014) was used to perform statistical tests.
Comparisons between multiple means are performed by
ANOVA, with post hoc tests performed if the F test was
significant for a main effect. Comparisons between two
means are performed by independent, two-tailed, Welch
t tests (which do not assume equal variance between
groups) unless otherwise stated. Correction for multiple
comparisons is made using the Bonferroni method.
P< 0.05was considered statistically significant (∗P< 0.05,
∗∗P < 0.01 and ∗∗∗P < 0.001.
Materials
NMDA, NMDA receptor antagonists, ifenprodil and
TTX were purchased from Tocris Bioscience (Bristol,
UK). Media, media supplements, Lipofectamine 2000,
fetal bovine serum, antibiotic/antimycotic and B-27 were
purchased from Invitrogen (Carlsbad, CA, USA). The
remaining substanceswere purchased fromSigma-Aldrich
(St Louis, MO, USA) unless otherwise stated.
Results
GluN2AN615K reduces Mg2+ blockade in triheteromeric
NMDA receptors
We first investigated Mg2+ blockade in GluN1/
GluN2AN615K diheteromers expressed in HEK293T
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cells (Fig. 1). Consistent with previous work (Endele
et al. 2010), we found that the GluN2AN615K variant
resulted in negligible Mg2+ blockade at approximately
physiological concentrations. We next investigated the
impact of the GluN2AN615K variant when expressed
as part of triheteromeric NMDA receptors containing
wild-type GluN2 subunits (Fig. 1). Accordingly, we
employed receptor subunits with modified endoplasmic
reticulum retention signals as developed by Hansen
et al. (2014) to express receptors containing zero, one
or two GluN2AN615K subunits partnered with wild-type
GluN2A or GluN2B subunits. Receptors containing
only one GluN2AN615K subunit continued to exhibit
markedly reduced Mg2+ blockade, with a blockade
intermediate between wild-type and GluN2AN615K
diheteromers (Fig. 1A and B). Unexpectedly, the identity
of the wild-type subunit partnered with GluN2AN615K
impacted on Mg2+ blockade, with a GluN2BWT partner
showing lower Mg2+ blockade than a GluN2AWT partner
(Fig. 1A and B). We confirmed that the modified
C-termini did not themselves influence Mg2+ blockade
(Fig. 1C).
Figure 1. GluN2AN615K reduces Mg2+ blockade in triheteromeric NMDA receptors
A, representative whole-cell, voltage clamp recordings from HEK293T cells expressing NMDA receptors containing
wild-type GluN2A diheteromers, GluN2A/2B triheteromers and GluN2AN615K-containing diheteromers and
triheteromers, partnered with either GluN2AWT or GluN2BWT. All subunits, including wild-type, had modified
endoplasmic reticulum signals. The traces show responses to glutamate (1 mM) and blockade by Mg2+ (1 mM)
in the continuous presence of glycine (100 μM), held at –60 mV. B, summary data showing percentage blockade
by Mg2+ for each receptor composition. A one-way ANOVA showed a significant effect of receptor subunit
composition (F4,64 = 346, P < 2 × 10–16). Post hoc Bonferroni corrected t tests showed that GluN2AN615K
diheteromeric receptors had a significantly reduced Mg2+ blockade (9 ± 1%, n = 7) compared to GluN2AWT
diheteromers (107 ± 2%, n = 7, t7.3 = 42, P = 5 × 10–10). Triheteromeric receptors containing only one
GluN2AN615K subunit also showed a marked reduction in Mg2+ blockade, whether partnered with one GluN2AWT
subunit (53 ± 2%, n = 20), compared with GluN2AWT diheteromers (t19.9 = 16.5, P = 2 × 10–12) or partnered
with one GluN2BWT subunit (36 ± 1%, n = 20), compared with GluN2AWT/2BWT (103 ± 1%, n = 15, t32.6 = 36.9,
P = 9 × 10–16). The reduction in Mg2+ blockade was greater in GluN2AN615K subunits partnered with GluN2BWT
than with GluN2AWT (t29.4 = 6.3, P = 3 × 10–6). Some traces show greater than 100% blockade by Mg2+,
reflecting a small contamination of the bath fluid (baseline exposure) by glutamate. C, summary data showing
percentage blockade by Mg2+ for NMDA receptors with and without modified C-termini. A two-way ANOVA
showed a significant influence of C-terminus tag (F1,35 = 8.0, P = 0.00785) and a significant effect of receptor
subunit composition (F2,35 = 2635, P < 2 × 10–16), although there was no significant interaction (F2,35 = 1.3,
P = 0.28). However, post hoc Bonferroni corrected t tests showed no significant effect of modifying C-termini
with engineered tags for any subunit.
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Figure 2. GluN2AN615K does not alter glutamate deactivation
A and B, representative whole-cell, voltage clamp recordings from HEK293T cells expressing NMDA receptors
containing wild-type GluN2A diheteromers, GluN2A/2B triheteromers and GluN2AN615K containing diheteromers
and triheteromers, partnered with either GluN2AWT or GluN2BWT. All subunits, including wild-type, had modified
endoplasmic reticulum signals. The traces show deactivation following 5 ms exposure to glutamate (1 mM) and
glycine (100 μM) in the absence of Mg2+ when held at –60 mV. Responses are normalized to their peak amplitudes.
C, summary data showing weighted time constants fitted to the glutamate deactivation curves. A one-way ANOVA
showed a significant effect of receptor subunit composition (F4,64 = 14, P = 3 × 10–8). Post hoc Bonferroni
corrected t tests showed that GluN2AWT/2B triheteromers had a slower deactivation time constant (77 ± 4 ms;
n = 15), than GluN2AWT diheteromers (45 ± 4 ms; n = 7; t17 = 6.2, P = 4 × 10–5). GluN2AWT diheteromers
were indistinguishable from GluN2AN615K diheteromers (41 ± 3; n = 7; t11 = 0.9, P  0.4), with GluN2AN615K
and GluN2AN615K/2A (49 ± 2 ms, n = 20) also showing no difference (t10.9 = 2.6, P = 0.1). GluN2AN615K/2B
triheteromers (79 ± 6, n = 20) showed a slower deactivation rate than GluN2AN615K diheteromers (t10.9 = 2.6,
P = 5 × 10–5)). D, summary data showing current density (peak amplitude/capacitance) for cells expressing
diheteromeric and triheteromeric receptor combinations (for other experiments, only cells with a current response
of between 100 and 1000 pA were used to allow accuracy without escape of unwanted subunit combinations but,
here, all traces are included). A one-way ANOVA showed no effect of receptor subunit composition (F4,104 = 2.1,
P = 0.08). E, summary data showing weighted time constants fitted to glutamate deactivation curves. Modifying
the C-terminus with engineered peptide tags designed to vary retention in the endoplasmic reticulum had no
effect on glutamate deactivation in diheteromeric wild-type receptors containing GluN2AWT or GluN2BWT, or in
those containing GluN2AN615K. A two-way ANOVA showed no significant influence of C terminus tag (F1,35 = 4.0,
P = 0.054), a significant effect of NMDAR subunit composition (F2,35 = 226, P < 2 × 10–16) and no significant
interaction (F2,35 = 2.5, P = 0.1).
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GluN2AN615K does not influence glutamate
deactivation
Previously, GluN2A/2B triheteromer glutamate
deactivation rates have been found to be intermediate
between those of GluN2A and GluN2B diheteromers
(Hansen et al. 2014; Stroebel et al. 2014). We used
fast applications of glutamate onto HEK293T cells to
replicate this finding, and we also demonstrated that
GluN2AN615K does not influence glutamate deactivation
rates (Fig. 2A–C). Current density showed a trend towards
lower levels in cells expressing GluN2AN615K-containing
receptors, although this was not statistically significant
(Fig. 2D). We also confirmed that the C-terminus
modifications required for the generation of triheteromers
do not influence glutamate deactivation rates in wild-type
or GluN2AN615K-containing receptors (Fig. 2E).
GluN2AN615K reduces single-channel conductance in
diheteromeric and triheteromeric NMDA receptors
The ‘N+1’ residue altered by the GluN2AN615K variant
is an ion-channel lining residue and contributes to form
one of the narrowest regions of the receptor pore (Song
et al. 2018). We therefore hypothesized that the variant
would influence ion permeation in addition to Mg2+
blockade, and investigated single channel conductance.
We found that the GluN2AN615K variant lead to a sub-
stantial four-fold reduction in single-channel conductance
in GluN2AN615K-containing diheteromers (Fig. 3A, B, E
and F). As a control, we confirmed that the modified
C-termini did not influence conductance (Fig. 3D).
In view of the marked effect of only one GluN2AN615K
subunit on Mg2+ blockade in NMDA receptors, we
hypothesized thatGluN2AN615K containing triheteromeric
receptors would also show a conductance intermediate
between GluN2AWT and GluN2AN615K diheteromers. Our
recordings from cells expressing triheteromeric receptors
showed a more complex picture than expected: the vast
majority of GluN2AN615K triheteromeric patches showed
channels with two conductances (Fig. 3C, E and F). One
conductance was indeed intermediate between that of
GluN2AWT andGluN2AN615K diheteromers; the other was
a prominent subconductance close in value to the primary
conductance of GluN2AN615K diheteromers.
We conducted some additional analyses to investigate
two alternative explanations that could mediate
what appears to be a prominent subconductance
in GluN2AN615K containing triheteromeric NMDA
receptors. One alternative explanation is that the
higher conductance represents simultaneous openings
of two triheteromeric channels. However, the higher
conductance was equal to more than double the lower
conductance (44 pS vs. 15 pS and 44 pS vs. 16 pS) (Fig. 3F).
We therefore concluded that the upper conductance did
not represent the simultaneous opening of two identical
lower conductance triheteromeric channels.
Another alternative explanation could be that the
patch contains one triheteromeric channel and one
diheteromeric channel that has ‘escaped’ retention in
the endoplasmic reticulum. To explore this possibility,
we compared events attributable to the simultaneous
opening and/or closing of two channels in patches
expressing triheteromers vs. patches expressing multiple
diheteromericGluN2AN615K receptors and found far fewer
such events associated with multiple diheteromers than
with triheteromers [GluN2AN615K diheteromers: 4 ± 2%
of openings (n = 7) vs. GluN2AN615K/2A triheteromers:
25 ± 1% of openings (n = 6) (t10.1 = 7.8, P = 2.8 × 10–5)
and GluN2AN615K/2B triheteromers: 19± 2% of openings
(n = 16) (t17.0 = 4.7, P = 3.9 × 10–4)].
We also assessed mean open times, finding that
the GluN2AN615K/2A triheteromeric subconductance
openings were briefer than those observed for
GluN2AN615K diheteromers (Fig. 3G). This argues against
the possibility that the similar conductance is mediated
by GluN2AN615K diheteromeric receptors present in
triheteromer-expressing patches. Such diheteromeric
‘escape currents’ can potentially arise when expression
levels are high (Hansen et al. 2014) and, indeed, we
did observe a small number of putative triheteromeric
receptor patches (five out of 27 patches) in which only
one conductance was observed (four with conductances
close to wild-type diheteromers; one with a conductance
close to 2A N615K diheteromers). Because these patches
presumably contained escaped diheteromeric receptors,
theywere excluded from the analysis. Overall, our findings
suggest that the GluN2AN615K variant results in a marked
reduction in NMDA receptor single channel conductance
when one or two copies are present. When two copies are
present in a receptor, a single low conductance is seen.
When one copy is present, two conductances are seen: low
and intermediate.
GluN2AN615K reduces Mg2+ blockade and current
density in cultured neurons
To complete our investigation, we wished to explore
whether the pronounced effects of GluN2AN615K seen
in NMDA receptors expressed in a human cell line
would also be seen in receptors expressed in primary
neurons, subject to neuronal specific trafficking and
regulation. Accordingly, we used transient transfection
to overexpress GluN2AWT and GluN2AN615K subunits
in mouse primary cortical neurons. The resulting
NMDA receptor population probably comprised a
mixture of diheteromeric and triheteromeric GluN2B and
GluN2A-containing receptors, formed from both end-
ogenous GluN2B subunits and transfected subunits. We
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Figure 3. GluN2AN615K reduces single-channel conductance in triheteromeric NMDA receptors
A–C, representative voltage clamp recordings made from cell-attached patches from HEK293T cells
expressing NMDA receptors containing wild-type GluN2A diheteromers, GluN2A/2B triheteromers and
GluN2AN615K-containing diheteromers and triheteromers, partnered with either GluN2AWT or GluN2BWT. All sub-
units, including wild-type, had modified endoplasmic reticulum signals. The traces show single-channel currents in
the presence of glutamate (1 mM) and glycine (100 μM). The pipette potentials used for the traces illustrated
in (A) to (C) were +120, +140 and +140 mV, respectively. ‘C’ = closed; ‘g1’ = first conductance fitted;
‘g2’ = second conductance fitted. A number of transitions between the two conductance states can be seen
in (C). D, summary data showing single channel conductance for receptors with and without modified C-termini.
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first confirmed the expression of transfected GluN2A sub-
units (wild-type or GluN2AN615K) by demonstrating a
reduction in inhibition by ifenprodil (a selective GluN2B
negative allostericmodulator) compared toneurons trans-
fected with an inert control, which express predominantly
GluN2B at DIV 9 (McKay et al. 2012) (Fig. 4A–D). We
next assessed the impact of the GluN2AN615K mutation on
Mg2+ blockade, in the presence and absence of ifenprodil
(Fig. 4A–C and E). We found that Mg2+ blockade was
reduced in neurons transfected with GluN2AN615K and
that this effect was more pronounced in the presence of
ifenprodil,whenahigherproportionof activated receptors
contain GluN2A subunits. Third, we assessed the impact
of GluN2AN615K on current density (Fig. 4A–C and F). We
found that current density was reduced in neurons trans-
fected with GluN2AN615K and this effect was again more
pronounced in the presence of ifenprodil. This reduction
in current density is consistent with the reduction in
conductance we observed previously (Fig. 3). Taken
together, these results show that, when the GluN2AN615K
mutation is expressed in cells which endogenously express
NMDA receptors, it continues to have a profound
influence on Mg2+ blockade and on current density.
Discussion
In the present study, we investigated the functional
consequences of GluN2AN615K, a heterozygous missense
variant found to have arisen de novo in two unrelated
people with early onset epileptic encephalopathy. Using
heterologous systems, we showed that the GluN2AN615K
variant results in major alterations to physiologically
crucial aspects of NMDA receptor function: an almost
complete loss of Mg2+ blockade and a four-fold reduction
in conductance. Importantly, the variant continues
to markedly reduce Mg2+ blockade and conductance
when expressed in NMDA receptor triheteromers with
one wild-type GluN2 subunit, and also continues to
have effect when expressed in cortical neurons. These
findings strengthen the evidence that the GluN2AN615K
variant causes the severe neurodevelopmental disorder
experienced by its carriers.
GluN2AN615K reduces Mg2+ blockade
Themarked reduction inMg2+ blockade that we observed
with the GluN2AN615K mutation is in keeping with pre-
vious work identifying the affected residue as important
for Mg2+ blockade (Wollmuth et al. 1998) and with
the disruptive replacement of an asparagine with a
positively-charged lysine. Our finding is also consistent
with previous work reporting minimal Mg2+ blockade
in GluN2AN615K diheteromers (Endele et al. 2010). We
additionally demonstrated a reduction in Mg2+ blockade
when GluN2AN615K is expressed in primary neurons. The
smaller magnitude of reduction in Mg2+ blockade seen
in neurons probably reflects the presence of endogenous
GluN2B subunits. We directly addressed the impact of
GluN2AN615K when expressed as part of triheteromeric
NMDA receptors with wild-type partner subunits and
found that Mg2+ blockade was reduced to an inter-
mediate extent. This is an important finding because
disease-associated mutations in GRIN2A have so far only
been found heterozygously. Observing an effect of the
variant despite the presence of wild-type subunits further
supports a role for GluN2AN615K in disease causation.
This finding indirectly supports the disease relevance of
other NMDA receptor pore mutations where functional
consequences have been established in diheteromers
(Fedele et al. 2018; Ferna´ndez-Marmiesse et al. 2018).
Interestingly, we observed an impact of partner subunit
identity on Mg2+ blockade in GluN2AN615K-containing
triheteromers: receptors with a wild-type GluN2A partner
subunit showed higher Mg2+ blockade than those with a
wild-type GluN2B partner subunit. However, we did not
A two-way ANOVA showed no significant influence of C-terminus tag (F1,62 = 0.6, P = 0.42), a significant
effect of receptor subunit composition (F2,62 = 278, P < 2 × 10–16) and a significant interaction (F2,62 = 5.7,
P = 0.006). E, representative amplitude histograms showing fitted normal distributions, superimposed from
three different patches. The means of the fitted distributions were used to calculate conductance. For the patch
expressing a GluN2AN615K-containing triheteromer, two peaks can be seen: the prominent subconductance and
the less frequent intermediate conductance. F, summary data showing conductances, calculated by plotting
current amplitudes against pipette potential (at least three potentials within range + 40 to + 180 mV). A two-way
ANOVA showed a main effect of subunit (F4,70 = 121, P < 2 × 10–16) and of conductance level (g1 vs. g2;
F1,70 = 196, P < 2 × 10–16), with no significant interaction. Post hoc Bonferroni corrected t tests showed that
GluN2AN615K diheteromeric receptors had a significantly lower conductance (18 ± 2 pS; n = 11) than GluN2AWT
diheteromers (69 ± 3 pS; n = 12; t15.4 = 13.7, P = 2 × 10–9). Triheteromeric receptors containing only one
GluN2AN615K subunit also showed a marked reduction in intermediate conductance (g2), whether partnered with
one GluN2AWT subunit (44 ± 1 pS; n = 6), compared with GluN2AWT diheteromers (t13.5 = 7.0, P = 3 × 10–5) or
with one GluN2BWT subunit (44 ± 1 pS; n = 16), compared with GluN2AWT/2BWT (56 ± 2 pS; n = 10; t18.4 = 4.2,
P = 0.003). The reduction in conductance was no greater in GluN2AN615K subunits partnered with GluN2BWT than
with GluN2AWT (t19.1 = 0.06, P > 0.9). G, summary data showing receptor mean open times calculated by fitting
single exponentials to open time distributions from individual patches. Only the lower conductance openings were
fitted for GluN2AN615K/2A triheteromers, which showed briefer open times than GluN2AN615K diheteromers (2A
N615K/2A: 1.83 ± 0.07 ms; n = 6 vs. 2A N615K 2.42 ± 0.19 ms, n = 11; t12.5 = 2.9, P = 0.014).
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Figure 4. GluN2AN615K reduces Mg2+ blockade and current density in cultured neurons.
A–C, representative whole-cell, voltage clamp recordings made from DIV 9 primary mouse cortical neurons trans-
iently transfected with an inert control: β globin (A), GluN2AWT (B) or GluN2AN615K (C). Traces show the response to
saturating NMDA (150 μM) and inhibition by Mg2+ (1 mM), before and after a 1 min application of ifenprodil (3 μM)
(a selective GluN2B negative allosteric modulator). D, summary data showing percentage inhibition by ifenprodil.
A one-way ANOVA showed a significant effect of transfected subunit (F2,42 = 46, P = 2.8 × 10–11), with post hoc
Bonferroni corrected t tests indicating that neurons transfected with GluN2AWT showed lower ifenprodil sensitivity
than control transfection cells (WT: 32 ± 3; n = 15; globin 75 ± 2; n = 15; t21.9 = 10.7, P = 1.0 × 10–9), as
did neurons transfected with GluN2AN615K (43 ± 4; n = 15; t20.0 = 7.2, P = 1.9 × 10–6) and with no difference
between GluN2A and GluN2AN615K (t27.3 = 1.9, P = 0.19). These results confirm that the GluN2AN615K sub-
units have been successfully trafficked to the surface in neurons. E, summary data showing Mg2+ blockade
in the presence and absence of ifenprodil. Squares show blockade without ifenprodil; triangles show blockade
with ifenprodil. Solid shapes represent means; hollow shapes are individual cells. A two-way ANOVA showed a
significant effect of transfected subunit (F2,42 = 111, P = 2 × 10–16) and the presence of ifenprodil (F1,42 = 31,
P = 1.9 × 10–6), with a significant interaction (F2,42 = 90, P = 6.7 × 10–16). Post hoc Bonferroni corrected t tests
showed lower Mg2+ blockade in the absence of ifenprodil in neurons transfected with GluN2AN615K compared to
GluN2AWT (WT: 93 ± 1%; n = 15; N615K 52 ± 5%; n = 15; t16.7 = 8.2, P = 9.7 × 10–7), although there was
no difference between GluN2AWT and control (globin: 97 ± 1%; n = 15; t23.3 = 2.2, P = 0.13). In the presence
of ifenprodil, the reduction in Mg2+ blockade associated with GluN2AN615K vs. wild-type was even more marked
(WT: 95 ± 1%; n = 15; N615K 31 ± 5%; n = 15; t15.4 = 12.1, P = 8.4 × 10–9). F, summary data showing
current density in the presence and absence of ifenprodil. As with Mg2+ blockade, we found that current density
was reduced in neurons transfected with GluN2AN615K, and this effect was more pronounced in the presence of
ifenprodil. A two-way ANOVA showed a significant effect of transfected subunit (F2,42 = 9.4, P = 0.0004) and the
presence of ifenprodil (F1,42 = 178, P = 2× 10–16), with a significant interaction (F2,42 = 9.2, P = 0.0005). Post hoc
Bonferroni corrected t tests showed lower current density in the absence of ifenprodil in neurons transfected with
GluN2AN615K compared to GluN2AWT (WT: 58 ± 5 pA pF–1; n = 15; N615K 40 ± 4 pA pF–1; n = 15; t27.3 = 2.7,
P = 0.037), although there was no difference between GluN2AWT and control (globin: 45 ± 4 pA pF–1; n = 15;
t27.4 = 1.9, P = 0.22). In the presence of ifenprodil, the reduction in current density associated with GluN2AN615K
vs. wild-type was even more marked (WT: 38 ± 4 pA pF–1; n = 15; N615K 23 ± 3 pA pF–1; n = 15) (t27.8 = 3.3,
P = 0.009).
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see an impactofpartner subunit identityon single-channel
conductance. The mechanism of this intriguing finding
and the extent to which it applies to other receptor
properties requires additional study.
A reduction in Mg2+ blockade would be hypo-
thesized tohave substantial impactonneuronalphysiology
and synaptic plasticity because voltage-dependent Mg2+
blockade is essential to the role of the NMDA receptor
as a molecular coincidence detector (Huganir & Nicoll,
2013). Alterations to this property could therefore be anti-
cipated to result in deficits in learning and memory, as
may be reflected in the severe and profound intellectual
disability of carriers. However, plasticity is dependent on
many interacting factors: additional receptor properties
such as calcium permeability, expression of other NMDA
receptor subunits and expression of other receptor types.
Furthermore, deficits in plasticity caused by reduced or
increased expression of NMDA receptor subunits have
been associated with behavioural consequences in several
(Sakimura et al. 1995; Kiyama et al. 1998; Roberts et al.
2009) but not all studies (Okabe et al. 1998). Further
studies are needed to assess the potential impact of the
GluN2AN615K variant on synaptic plasticity, which would
be aided by a transgenic animal model.
GluN2AN615K reduces conductance
We found that the GluN2AN615K variant reduced
single-channel conductance by around four-fold when
expressed as diheteromers. Triheteromers containing only
one GluN2AN615K subunit showed two conductances:
one similar to GluN2AN615K diheteromers and one inter-
mediate conductance equivalent to around two-thirds of
wild-type. We also found that NMDA-evoked current
density was reduced in neurons expressing GluN2AN615K,
suggesting that any acute compensation by other receptor
subunits was insufficient to overcome the reduction in
conductance associated with the GluN2AN615K variant.
Our finding of reduced conductance adds to pre-
vious work reporting similarly marked reductions in
conductance following mutations of equivalent residues
neighbouring the location of the GluN2AN615K variant
in GluN1 and GluN2B subunits (Behe et al. 1995; Pre-
mkumar et al. 1997; Schneggenburger & Ascher, 1997).
In addition to this probable direct impact of the altered
residue on ion permeation through the narrow inter-
nal region of the pore (Song et al. 2018), it is possible
that other charged regions that strongly influence ion
permeation (e.g. the DRPEER motif in the GluN1 sub-
unit) (Wollmuth, 2018) may also be indirectly affected
by the GluN2AN615K variant, contributing to effects on
single-channel conductance. Our finding that glutamate
deactivation rates are unaffected by the mutation shows
that the overall time course of receptor openings is similar.
A reduction in conductance is of physiological importance
because it implies that less charge is passed by activated
NMDA receptors containing GluN2AN615K subunits. This
would reduce the ability of a receptor to contribute
to neuronal excitability, and also potentially alter the
receptor’s ionotropic signaling pathways.
In summary, the present study has strengthened the
evidence indicating that the disease-associated variant
GluN2AN615K is associated with substantial changes in
physiologically crucial properties of NMDA receptors.
This information can be used to inform genetic
counselling. Our work highlights NMDA receptor-related
synaptic transmission as probable candidates for
disruption in the pathogenesis of neurodevelopmental
disorders. Future work could usefully explore the impact
of this mutation in vivo in synaptic plasticity at circuit and
behavioural levels.
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